Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, describes the mechanism of action of KER-050, a product that alters TGF-β signaling, in patients with myelofibrosis (MF). Prof. Harrison highlights an ongoing Phase II trial (NCT05037760) of KER-050 in patients with MF that has reported promising early results with no major safety concerns. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.